Robert M Tulloh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3918633/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. Journal of Heart and Lung Transplantation, 2019, 38, 879-901.	0.6	266
2	A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. The Lancet Child and Adolescent Health, 2021, 5, 133-141.	5.6	228
3	Transforming Growth Factor-Î ² Receptor Mutations and Pulmonary Arterial Hypertension in Childhood. Circulation, 2005, 111, 435-441.	1.6	222
4	Novel Method of Quantifying Pulmonary Vascular Resistance by Use of Simultaneous Invasive Pressure Monitoring and Phase-Contrast Magnetic Resonance Flow. Circulation, 2004, 110, 826-834.	1.6	156
5	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1800332.	6.7	110
6	A Randomized Controlled Trial of Motavizumab Versus Palivizumab for the Prophylaxis of Serious Respiratory Syncytial Virus Disease in Children With Hemodynamically Significant Congenital Heart Disease. Pediatric Research, 2011, 70, 186-191.	2.3	87
7	Cardiac Magnetic Resonance Imaging After Stage I Norwood Operation for Hypoplastic Left Heart Syndrome. Circulation, 2005, 112, 3256-3263.	1.6	83
8	Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. Journal of Pediatrics, 2020, 222, 261-262.	1.8	83
9	Kawasaki disease: a prospective population survey in the UK and Ireland from 2013 to 2015. Archives of Disease in Childhood, 2019, 104, 640-646.	1.9	79
10	Measurement of total pulmonary arterial compliance using invasive pressure monitoring and MR flow quantification during MR-guided cardiac catheterization. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H1301-H1306.	3.2	77
11	Kawasaki disease in children. Heart, 2009, 95, 787-792.	2.9	70
12	Cardiac function and hemodynamics in Kenyan children with severe malaria. Critical Care Medicine, 2010, 38, 940-945.	0.9	68
13	Corticosteroids for the treatment of Kawasaki disease in children. The Cochrane Library, 2017, 2017, CD011188.	2.8	68
14	Intermediate-term outcome following the fontan operation: a survival, functional and risk-factor analysisa~†. European Journal of Cardio-thoracic Surgery, 2005, 28, 529-535.	1.4	61
15	Takayasu's disease: a review. Cardiology in the Young, 2008, 18, 250-259.	0.8	61
16	Lifetime cardiovascular management of patients with previous Kawasaki disease. Heart, 2020, 106, 411-420.	2.9	54
17	The utility of sildenafil in pulmonary hypertension: a focus on bronchopulmonary dysplasia. Archives of Disease in Childhood, 2013, 98, 613-617.	1.9	53
18	Pulmonary hypertension in congenital heart disease. Future Cardiology, 2018, 14, 343-353.	1.2	53

#	Article	IF	CITATIONS
19	Management of pulmonary hypertension in Down syndrome. European Journal of Pediatrics, 2011, 170, 915-921.	2.7	50
20	An echocardiographic study of tetralogy of Fallot in the fetus and infant. Cardiology in the Young, 2003, 13, 240-247.	0.8	47
21	Atrial Septal Defect with Failure to Thrive in Infancy: Hidden Pulmonary Vascular Disease?. Pediatric Cardiology, 2002, 23, 528-530.	1.3	45
22	Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiology in the Young, 2003, 13, 420-423.	0.8	44
23	Maturation of the Contractile Response and Its Endothelial Modulation in Newborn Porcine Intrapulmonary Arteries. Pediatric Research, 1995, 38, 25-29.	2.3	40
24	Echocardiographic Screening for Pulmonary Hypertension in CongenitalÂHeart Disease. Journal of the American College of Cardiology, 2018, 72, 2778-2788.	2.8	38
25	Pulmonary arterial hypertension exacerbated by ruxolitinib. Haematologica, 2015, 100, e244-e245.	3.5	37
26	Pulse oximetry screening for critical congenital heart defects: a European consensus statement. The Lancet Child and Adolescent Health, 2017, 1, 88-90.	5.6	34
27	Percutaneous retrieval of central venous catheter fragments. Archives of Disease in Childhood, 2002, 87, 149-150.	1.9	33
28	Cellular and molecular basis of RV hypertrophy in congenital heart disease. Heart, 2016, 102, 12-17.	2.9	33
29	Congenital heart disease in relation to pulmonary hypertension in paediatric practice. Paediatric Respiratory Reviews, 2005, 6, 174-180.	1.8	32
30	Recurrent skin peeling following Kawasaki disease. Archives of Disease in Childhood, 2000, 83, 353-355.	1.9	29
31	The Perception of a Three-Dimensional-Printed Heart Model from the Perspective of Different Stakeholders: A Complex Case of Truncus Arteriosus. Frontiers in Pediatrics, 2017, 5, 209.	1.9	29
32	Kawasaki disease incidence in children and adolescents: an observational study in primary care. British Journal of General Practice, 2016, 66, e271-e276.	1.4	28
33	Paediatric pulmonary hypertension and sildenafil: current practice and controversies. Archives of Disease in Childhood: Education and Practice Edition, 2013, 98, 141-147.	0.5	27
34	Retrospective prenatal diagnosis of scimitar syndrome aided by three-dimensional power Doppler imaging. Ultrasound in Obstetrics and Gynecology, 2001, 17, 449-452.	1.7	25
35	Does the persistence of pulsatile antegrade pulmonary blood flow following bidirectional Glenn procedure affect long term outcome?â€. European Journal of Cardio-thoracic Surgery, 2015, 47, 154-158.	1.4	25
36	Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease. Heart Lung and Circulation, 2017, 26, 1113-1116.	0.4	24

#	Article	IF	CITATIONS
37	NF-κB inhibition prevents acute shear stress-induced inflammation in the saphenous vein graft endothelium. Scientific Reports, 2020, 10, 15133.	3.3	24
38	Interventional cardiac catheterisation in congenital heart disease. Archives of Disease in Childhood, 2004, 89, 1168-1173.	1.9	23
39	High haematocrit in cyanotic congenital heart disease affects how fibrinogen activity is determined by rotational thromboelastometry. Thrombosis Research, 2013, 132, e145-e151.	1.7	23
40	The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease. Cardiology in the Young, 2005, 15, 274-278.	0.8	19
41	Treatment of pediatric pulmonary hypertension. Vascular Health and Risk Management, 2009, 5, 509.	2.3	19
42	Etiology, Diagnosis, and Pharmacologic Treatment of Pediatric Pulmonary Hypertension. Paediatric Drugs, 2009, 11, 115-128.	3.1	19
43	CHD and respiratory syncytial virus: global expert exchange recommendations. Cardiology in the Young, 2017, 27, 1504-1521.	0.8	19
44	Primary repair versus surgical and transcatheter palliation in infants with tetralogy of Fallot. Heart, 2018, 104, 1864-1870.	2.9	19
45	Assessment of Myocardial Function in Kenyan Children With Severe, Acute Malnutrition. JAMA Network Open, 2019, 2, e191054.	5.9	18
46	Lung Function, Inflammation, and Endothelinâ€₁ in Congenital Heart Disease–Associated Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2018, 7, .	3.7	17
47	Kawasaki disease. BMJ, The, 2014, 349, g5336-g5336.	6.0	16
48	Cardiac problems in Down syndrome. Paediatrics and Child Health (United Kingdom), 2015, 25, 23-29.	0.4	16
49	Changes in contractile protein expression are linked to ventricular stiffness in infants with pulmonary hypertension or right ventricular hypertrophy due to congenital heart disease. Open Heart, 2018, 5, e000716.	2.3	15
50	Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease. Pulmonary Circulation, 2018, 8, 1-12.	1.7	15
51	Sildenafil in Infants and Children. Children, 2017, 4, 60.	1.5	14
52	A pilot randomised controlled trial investigating a mindfulness-based stress reduction (MBSR) intervention in individuals with pulmonary arterial hypertension (PAH): the PATHWAYS study. Pilot and Feasibility Studies, 2018, 4, 78.	1.2	14
53	Adaptations of aortic and pulmonary artery flow parameters measured by phase-contrast magnetic resonance angiography during supine aerobic exercise. European Journal of Applied Physiology, 2014, 114, 1013-1023.	2.5	12
54	Management and therapeutic options in pediatric pulmonary hypertension. Expert Review of Cardiovascular Therapy, 2006, 4, 361-374.	1.5	11

#	Article	IF	CITATIONS
55	Evolving Management of Pediatric Pulmonary Arterial Hypertension: Impact of Phosphodiesterase Inhibitors. Pediatric Cardiology, 2013, 34, 213-219.	1.3	11
56	Corticosteroids for the treatment of Kawasaki disease in children. The Cochrane Library, 2022, 2022, .	2.8	11
57	Eisenmenger's syndrome:A review of the pathophysiology and therapeutic options. British Journal of Cardiac Nursing, 2008, 3, 138-145.	0.1	10
58	Atrial septal defect closure with an Amplatzer septal occluder fenestrated with a coronary stent in a child with pulmonary arterial hypertension. Cardiology in the Young, 2013, 23, 692-696.	0.8	10
59	Kawasaki disease: diagnosis, management and cardiac sequelae. Expert Review of Cardiovascular Therapy, 2007, 5, 553-561.	1.5	9
60	Sildenafil, pulmonary hypertension and bronchopulmonary dysplasia. Early Human Development, 2016, 102, 21-24.	1.8	9
61	Retrospective study of the impact of unrecognised Kawasaki disease, coronary aneurysm and ectasia. International Journal of Cardiology, 2017, 248, 308-313.	1.7	9
62	Surgical Repair of Tetralogy of Fallot With Absent Pulmonary Valve: Favorable Long-Term Results. Seminars in Thoracic and Cardiovascular Surgery, 2019, 31, 847-849.	0.6	9
63	Palliative care in pulmonary hypertension associated with congenital heart disease: systematic review and expert opinion. ESC Heart Failure, 2021, 8, 1901-1914.	3.1	9
64	An echocardiographic study of tetralogy of Fallot in the fetus and infant. Cardiology in the Young, 2003, 13, 240-7.	0.8	9
65	Role of NO in recovery from neonatal hypoxic pulmonary hypertension. Thorax, 1999, 54, 796-804.	5.6	8
66	Use of Pulmonary Arterial Hypertension Therapies in Patients with a Fontan Circulation: Current Practice Across the United Kingdom. Journal of the American Heart Association, 2022, 11, e023035.	3.7	8
67	Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiology in the Young, 2003, 13, 420-3.	0.8	8
68	Coronary arterial complications before and after the arterial switch operation: is the future clear?. Cardiology in the Young, 2002, 12, 164-171.	0.8	7
69	Sildenafil in bronchopulmonary dysplasia: safe to use?. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2015, 100, F369.2-F369.	2.8	7
70	Anomalous Left Coronary From the Pulmonary Artery Presenting as Ventricular Fibrillation After Persistent Ductus Arteriosus Ligation. Annals of Thoracic Surgery, 2015, 100, e9-e10.	1.3	7
71	The incidence of Kawasaki disease after vaccination within the UK preâ€school National Immunisation Programme: an observational THIN database study. Pharmacoepidemiology and Drug Safety, 2016, 25, 1331-1336.	1.9	7
72	Management of Adults With Congenital Heart Disease and Pulmonary Arterial Hypertension in the UK: Survey of Current Practice, Unmet Needs and Expert Commentary. Heart Lung and Circulation, 2018, 27, 1018-1027.	0.4	7

#	Article	IF	CITATIONS
73	Respiratory virus prophylaxis in congenital heart disease. Future Cardiology, 2018, 14, 417-425.	1.2	7
74	The cardiac proteome in patients with congenital ventricular septal defect: A comparative study between right atria and right ventricles. Journal of Proteomics, 2019, 191, 107-113.	2.4	7
75	Reply. Journal of Pediatrics, 2020, 224, 184-185.e1.	1.8	7
76	Surgical versus balloon valvotomy in neonates and infants: results from the UK National Audit. Open Heart, 2019, 6, e000938.	2.3	6
77	Age over 35 years is associated with increased mortality after pulmonary valve replacement in repaired tetralogy of Fallot: results from the UK National Congenital Heart Disease Audit database. European Journal of Cardio-thoracic Surgery, 2020, 58, 825-831.	1.4	6
78	Prevention and prophylaxis of respiratory syncytial virus in pediatric cardiology: a UK perspective. Future Cardiology, 2014, 10, 235-242.	1.2	5
79	Kawasaki disease and coronary artery aneurysms: from childhood to adulthood. Future Cardiology, 2017, 13, 491-501.	1.2	5
80	Recommendations from the Association for European Paediatric and Congenital Cardiology for training in pulmonary hypertension. Cardiology in the Young, 2019, 29, 1323-1327.	0.8	5
81	Strategies for the management of pulmonary arterial hypertension in patients with congenital heart disease. Journal of Congenital Cardiology, 2020, 4, .	0.5	5
82	Hypoplastic left heart syndrome: diagnosis and management. British Journal of Hospital Medicine, 2002, 63, 24-27.	0.2	4
83	Intermittent antegrade warm-blood versus cold-blood cardioplegia in children undergoing open heart surgery: a protocol for a randomised controlled study (Thermic-3). BMJ Open, 2020, 10, e036974.	1.9	4
84	Should we use steroids as primary therapy for Kawasaki disease?. Archives of Disease in Childhood, 2020, 105, 1120.1-1124.	1.9	4
85	Cardiac problems in Down syndrome. Paediatrics and Child Health (United Kingdom), 2011, 21, 25-31.	0.4	3
86	Giant coronary artery aneurysms in a 12-week-old infant with incomplete Kawasaki disease. BMJ Case Reports, 2018, 2018, bcr-2018-224479.	0.5	3
87	Comparison of the effect of inhaled anaesthetic with intravenous anaesthetic on pulmonary vascular resistance measurement during cardiac catheterisation. Cardiology in the Young, 2015, 25, 368-372.	0.8	2
88	Authors' response to â€~Aspirin dose for treatment of Kawasaki disease'. Archives of Disease in Childhood, 2015, 100, 300.2-301.	1.9	2
89	Outcomes following aortic valve procedures in 201 complex congenital heart disease cases—results from the UK National Audit. Interactive Cardiovascular and Thoracic Surgery, 2020, 31, 547-554.	1.1	2
90	Does Maintenance of Pulmonary Blood Flow Pulsatility at the Time of the Fontan Operation Improve Hemodynamic Outcome in Functionally Univentricular Hearts?. Pediatric Cardiology, 2021, 42, 1180-1189.	1.3	2

#	Article	IF	CITATIONS
91	Pulmonary arterial hypertension in adults with congenital heart disease: markers of disease severity, management of advanced heart failure and transplantation. Expert Review of Cardiovascular Therapy, 2021, 19, 837-855.	1.5	2
92	Inflammatory markers in Eisenmenger syndrome and their association with clinical outcomes. A cross-sectional comparative study. International Journal of Cardiology, 2021, 342, 34-38.	1.7	2
93	Cervical aortic arch with anomalous origin of the left subclavian artery from Kommerell's diverticulum. Cardiology in the Young, 1996, 6, 187-189.	0.8	1
94	Patent ductus arteriosus: an analysis of management. Cardiology in the Young, 2014, 24, 941-943.	0.8	1
95	Fifteen-minute consultation: rheumatic fever. Archives of Disease in Childhood: Education and Practice Edition, 2015, 100, 176-179.	0.5	1
96	Paediatric pulmonary hypertension: aetiology, pathophysiology and treatment. Paediatrics and Child Health (United Kingdom), 2017, 27, 50-57.	0.4	1
97	Can we avoid the complications of the Fontan operation in those with suboptimal anatomy?. International Journal of Cardiology, 2020, 302, 43-44.	1.7	1
98	Cortisol/cortisone levels and quality of life in individuals with pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-4.	1.7	1
99	Advanced therapies in complex congenital heart disease. Journal of Congenital Cardiology, 2020, 4, .	0.5	1
100	Advanced therapies in pulmonary arterial hypertension and congenital heart disease in people with Down syndrome. Journal of Congenital Cardiology, 2020, 4, .	0.5	1
101	The sinister course of an intramural right coronary artery. Cardiology in the Young, 2012, 22, 206-208.	0.8	0
102	Update on pulmonary arterial hypertension in children: management strategies and clinical utility of sildenafil. Pediatric Health, Medicine and Therapeutics, 2012, , 59.	1.6	0
103	Being mindful of pulmonary arterial hypertension. British Journal of Cardiac Nursing, 2013, 8, 127-133.	0.1	0
104	Use of phase-contrast magnetic resonance angiography to measure adaptations of aortic and pulmonary artery flow during supine aerobic exercise. Lancet, The, 2014, 383, S80.	13.7	0
105	Cardiovascular adaptation to extra uterine life. Paediatrics and Child Health (United Kingdom), 2018, 28, 549-555.	0.4	0
106	Congenital heart disease, pulmonary arterial hypertension and the UK's Drivers and Vehicle Licensing Agency: controversial new guidance. Pulmonary Circulation, 2019, 9, 1-2.	1.7	0
107	K (ATP) + Channels in Neonatal Pulmonary Vessels during Normal Development and Chronic Hypoxia. , 1994, , 213-224.		0

108 Inherited Pulmonary Arterial Hypertension. , 2018, , 741-753.

#	Article	IF	CITATIONS
109	Identification of atrial fibrillation in secondary care diabetes and vascular clinics: a pilot study. Future Cardiology, 2020, 16, 179-188.	1.2	0
110	Fifteen-minute consultation: Kawasaki disease: how to distinguish from other febrile illnesses: tricks and tips. Archives of Disease in Childhood: Education and Practice Edition, 2020, 105, 152-156.	0.5	0